AbbVie Next-Gen Combo Data Further Goal To Target Hard-To-Cure HCV Patients

With Viekira Pak missing sales expectations in hepatitis C, AbbVie Inc. has placed substantial hope on its next-generation combo glecaprevir/pibrentasvir with a special focus on difficult-to-treat HCV sub-populations. At the International Liver Congress, the Chicago-area pharma is presenting data demonstrating the fixed-dose combo can cure many HCV-infected patients with compensated cirrhosis without ribavirin add-on therapy.

On the opening day of the European Association for the Study of Liver Diseases meeting in Amsterdam, AbbVie reported that the glecaprevir 300 mg/pibrentasvir 120 mg regimen, combining a protease...